• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

In vitro study of normoxic epidermal growth factor receptor–induced hypoxia‐inducible factor‐1‐alpha, vascular endothelial growth factor, and BNIP3 expression in head and neck squamous cell carcinoma cell lines: Implications for anti–epidermal growth factor receptor therapy
ConclusionThe search for molecular predictors of sensitivity to gefitinib in HNSCC should be extended to the activation status of EGFR‐downstream pathways, phosphorylated protein kinase B, pMAPK, and HIF‐1α. © 2014 Wiley Periodicals, Inc. Head Neck, 2014
Source: Head and Neck - July 7, 2014 Category: ENT & OMF Authors: Pablo Secades, Inés Saenz Santa‐María, Anna Merlo, Carlos Suarez, María‐Dolores Chiara Tags: Original Article Source Type: research

In vitro study of normoxic epidermal growth factor (EGF)‐induced HIF‐1α, VEGF and BNIP3 expression in head and neck squamous cell carcinoma cell lines: implications for anti‐EGFR therapy
Conclusions The search for molecular predictors of sensitivity to gefitinib in HNSCC should be extended to the activation status of EGFR‐downstream pathways, pAkt, pMAPK, and HIF‐1α. Head Neck, 2014
Source: Head and Neck - May 2, 2014 Category: ENT & OMF Authors: Pablo Secades, Inés Saenz de Santamaría, Anna Merlo, Carlos Suarez, María‐Dolores Chiara Tags: Original Article Source Type: research

NFκB Silencing Induces Chromatin Acetylation and Ablates Resistance to Cisplatin in Head and Neck Cancer
Conclusion: Our results suggest that HDAC inhibitors and NFκB targeted therapies may represent viable adjuvant chemotherapy to revert HNSCC resistant to platinum-based therapies.
Source: Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics - January 21, 2014 Category: ENT & OMF Authors: ALINE CORREA ABRAHAO, LUCIANA O. ALMEIDA, LUCIANA K. ROSSELLI-MURAI, FERNANDA S. GIUDICE, ANDREIA M. LEOPOLDINO, CRISTIANE H. SQUARIZE, ROGERIO M. CASTILHO Tags: Online Only Articles Source Type: research

HRAS mutations and resistance to the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in head and neck squamous cell carcinoma cells
Conclusion: Activating HRAS mutations can confer erlotinib resistance in an HRAS mutant HNSCC cell line. Head Neck, 2013.
Source: Head and Neck - September 30, 2013 Category: ENT & OMF Authors: J. Hun Hah, Mei Zhao, Curtis R. Pickering, Mitchell J. Frederick, Genevieve A. Andrews, Samar A. Jasser, David R. Fooshee, Zvonimir L. Milas, Chad Galer, Daisuke Sano, William N. William, Edward Kim, John Heymach, Lauren A. Byers, Vali Papadimitrakopoulou Tags: Research Article Source Type: research

Gene silencing with siRNA targeting E6/E7 as a therapeutic intervention against head and neck cancer-containing HPV16 cell lines.
Conclusion: Our results indicate that siRNA E6 and/or E7 may have potential as a gene-specific therapy for human papillomavirus (HPV) type 16 (HPV16)-related squamous cell carcinoma of the head and neck (HNSCC). Objectives: To evaluate the effectiveness of siRNA targeting E6 and/or E7 on the in vitro and in vivo growth suppression of HPV16-related HNSCC. Methods: HPV16-related HNSCC (UM-SCC47) cell lines were used for the present study. Expression of HPV viral oncogenes E6 and/or E7 and their cellular targets, p53 and pRb, was evaluated by real-time PCR, Western blotting, and immunofluorescence staining. To study the effec...
Source: Acta Oto-Laryngologica - May 3, 2013 Category: ENT & OMF Authors: Adhim Z, Otsuki N, Kitamoto J, Morishita N, Kawabata M, Shirakawa T, Nibu KI Tags: Acta Otolaryngol Source Type: research